Erlotinib Recruiting Phase 3 Trials for EGFR Mutations / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02140333Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
NCT02714010EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC